Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM369 Phase I in Advanced Solid Tumors and Hematologic Malignancies
NCT05690581Phase 1Recruiting
- Sponsor
- InnoCare Pharma
- Start
- Feb 2023
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of CM369 in solid tumor and hematologic malignancy (2 arms), sponsored by InnoCare Pharma. Primary endpoints: Adverse events at 90 weeks, Serious Adverse events at 90 weeks and 1 more. Started Feb 2023; status: recruiting.
02
Drugs
CM369
03
Conditions
solid tumorhematologic malignancy
Beyond the preview
Go deeper on NCT05690581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05690581.